Treatment of Lennox-Gastaut Syndrome with Non-Convulsive Status Epilepticus
Clinical Scenario
This protocol addresses patients with Lennox-Gastaut syndrome (LGS) who develop non-convulsive status epilepticus (NCSE) — a recognised and clinically significant complication in this population that requires a targeted management approach.
Why This Situation Matters
Up to 75% of patients with LGS experience episodes of NCSE, making recognition and timely intervention a core consideration in this syndrome. NCSE in LGS presents distinct management challenges given the complex epilepsy background of these patients.
Treatment Approach & Clinical Goal
Management involves specific pharmacological therapy directed at the active NCSE episode. The treatment goal is to return the EEG to its pre-NCSE baseline pattern, with ongoing review to guide optimisation.
Full agent selection, sequencing, and monitoring are outlined in the complete regimen — not shown here.
References
DOI: 10.1002/epi4.13075
- Up to 75% of patients with LGS experience episodes of NCSE.
- NCSE should be treated with CLB and/or steroids (expert opinion), although there is currently no evidence for any agent or dosing regimen, and the use of steroids varies according to local protocol.
- High-dose intravenous VPA can also be effective, and there is emerging data that FFA can be used as a treatment option for NCSE in patients with LGS.
- The goal of treatment is to return the EEG to its pre-NCSE baseline pattern, and treatment should be optimized with ongoing review.
View source ↗